이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Genscript Biotech 관리

관리 기준 확인 1/4

Genscript Biotech's CEO는 Weihui Shao, Jul2021 에 임명되었습니다 의 임기는 3.08 년입니다. 는 HK$ 8.93M 가치에 해당하는 회사 주식의 0.034% 직접 소유합니다. 8.93M. 경영진과 이사회의 평균 재임 기간은 각각 3.7 년과 4.3 년입니다.

주요 정보

Weihui Shao

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	3.2yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	1.5yrs

최근 관리 업데이트

Recent updates

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Sep 16

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Aug 02

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Jun 05

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

May 10

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 13

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Mar 13

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 26

Is Genscript Biotech (HKG:1548) A Risky Investment?

Nov 21

Is Genscript Biotech (HKG:1548) A Risky Investment?

Aug 22

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Apr 04

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Apr 03

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 02

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Feb 07

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Dec 14

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 09

Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?

Mar 20

Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?

Feb 13

Did The Underlying Business Drive Genscript Biotech's (HKG:1548) Lovely 753% Share Price Gain?

Jan 09

Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?

Dec 05

CEO

Weihui Shao (44 yo)

3.2yrs

테뉴어

Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jiange Meng	Executive Chairman	9.1yrs	US$1.07m	0.013% $ 3.6m
Weihui Shao	CEO & COO	3.2yrs	데이터 없음	0.034% $ 9.3m
Ye Wang	Co-Founder	22.7yrs	US$615.00k	0.036% $ 10.0m
Shiniu Wei	Chief Financial Officer	3.8yrs	데이터 없음	데이터 없음
Fangliang Zhang	co-founder & Executive Director	1.8yrs	US$271.00k	데이터 없음
Li Zhu	Chief Strategy Officer & Executive Director	3.8yrs	US$529.00k	0.058% $ 16.0m
Ling Wong Wai	Company Secretary	9.1yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: 1548 의 관리팀은 경험 ( 3.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jiange Meng	Executive Chairman	9.1yrs	US$1.07m	0.013% $ 3.6m
Ye Wang	Co-Founder	9.3yrs	US$615.00k	0.036% $ 10.0m
Fangliang Zhang	co-founder & Executive Director	2.3yrs	US$271.00k	데이터 없음
Li Zhu	Chief Strategy Officer & Executive Director	3.8yrs	US$529.00k	0.058% $ 16.0m
Carl June	Member of Advisory Board	less than a year	데이터 없음	데이터 없음
George Church	Member of Advisory Board	5yrs	데이터 없음	데이터 없음
Alphonse Galdes	Independent Non-Executive Director	no data	데이터 없음	데이터 없음
David Liu	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Luquan Wang	Non-Executive Director	9.3yrs	데이터 없음	0.030% $ 8.2m
Yiu Leung Cheung	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음
Chenyang Shi	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음
Ethan Pan	Independent Non-Executive Director	no data	데이터 없음	데이터 없음

1.5yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 이사회: 1548 의 이사회는 경험(평균 재직 기간 1.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Genscript Biotech 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Genscript Biotech Corporation Announces Board Appointments

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Recent updates

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Genscript Biotech Corporation Announces Board Appointments

Consensus EPS estimates fall by 46%

First half 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

Full year 2023 earnings: EPS exceeds analyst expectations

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

New minor risk - Profitability

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Executive Chairman recently sold HK$610k worth of stock

Executive Chairman exercised options and sold HK$4.5m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Independent Non-Executive Director exercised options and sold HK$1.6m worth of stock

Non-Executive Director exercised options and sold HK$2.4m worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

Is Genscript Biotech (HKG:1548) A Risky Investment?

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Consensus revenue estimates fall by 19%

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Is Genscript Biotech (HKG:1548) A Risky Investment?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Less than half of directors are independent

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Is Genscript Biotech (HKG:1548) Using Debt Sensibly?

Consensus forecasts updated

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Co-Founder exercised options and sold HK$327k worth of stock

Genscript Biotech Corporation Announces Board Changes

Less than half of directors are independent

Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Consensus forecasts updated

Key Executive exercised options and sold HK$897k worth of stock

Board Member exercised options and sold HK$1.1m worth of stock

Board Member recently sold HK$2.1m worth of stock

Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?